Trial Profile
A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2020
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary) ; Levodopa/carbidopa (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Pharmacokinetics; Registrational
- Sponsors NeuroDerm
- 10 Nov 2018 This study has been completed in Spain.
- 13 Jun 2018 New trial record